For the quarter ending 2025-09-30, DSGN made $21,625,000 in revenue. -$16,997,000 in net income. Net profit margin of -78.60%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Research and development (including related party amounts of 228, 224, 686 and 670, respectively) | 14,589,000 | 15,738,000 | 11,087,500 | |
| General and administrative (including related party amounts of 130, 134, 395 and 405, respectively) | 4,722,000 | 5,831,000 | 4,508,250 | |
| Total operating expenses | 19,311,000 | 21,569,000 | 15,595,750 | |
| Loss from operations | -19,311,000 | -21,569,000 | -15,595,750 | |
| Interest income | 2,314,000 | 2,486,000 | 3,198,750 | |
| Net loss | -16,997,000 | -19,083,000 | -12,397,000 | |
| Net loss per share, basic | -0.3 | -0.34 | -0.22 | |
| Net loss per share, diluted | -0.3 | -0.34 | -0.22 | |
| Weighted-average shares of common stock outstanding, basic | 56,950,999 | 56,859,388 | 14,146,785.5 | |
| Weighted-average shares of common stock outstanding, diluted | 56,950,999 | 56,859,388 | 14,146,785.5 | |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)